Friends! In this video, I'm going to do an analysis on Brookfield stock
1 extracted signal · 1 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 17 Sept 2025, 21:28 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
The analysis focuses on Brookfield Corporation (BN), currently trading at $67.80. The analyst believes it is undervalued and should be trading at $80 to $85 in the short term. He mentions BN has outperformed global equity markets over the last 30 years with a 19% annualized return, compared to 11% for the S&P 500. Over the last 5 years, BN has delivered a 22% annual return. The analyst also discusses the company's business model which includes asset management, insurance, and real estate. He mentions the company is aiming for an annualized DE (distributable earnings) per share growth of 17% until 2030 with a longer-term growth rate for a 25% CAGR. He explains that the company owns about $12 billion worth of direct investments and generates about 54% of net profit.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.